Champions Oncology Reports Stable Revenue, Positive Adjusted EBITDA in Q1 2026

Champions Oncology (CSBR) reported Q1 FY26 revenue of $14 million, stable YoY, and positive adjusted EBITDA of $60,000, down from $2 million in the prior-year period. The company's cash position improved to $10.3 million, and management expects sequential revenue growth, expanded margins, and cash growth in the second half of the fiscal year. The data business has generated revenue for three consecutive quarters, and the company is seeking external partners and investment to advance its Corellia subsidiary.